XML 68 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Gilead Sciences Inc (Details) - USD ($)
$ in Thousands
 1 Months Ended 7 Months Ended 12 Months Ended
Oct. 14, 2022
Jun. 30, 2024
Jul. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2023
Collaboration and Other Agreements [Line Items]              
Revenues       $ 149,962 $ 58,749 $ 151,941  
Gilead | 2022 Gilead Collaboration And License Agreement              
Collaboration and Other Agreements [Line Items]              
Non-refundable upfront payment     $ 60,000        
Target nomination, option fees and milestone $ 1,700,000            
Revenues       1,500 1,500 $ 200  
Deferred revenue       56,800 58,300    
Deferred revenue, current       1,300 2,200    
Deferred revenue, noncurrent       55,500 56,100    
Gilead | Gilead First Research Program              
Collaboration and Other Agreements [Line Items]              
Revenues       7,800 800    
Deferred revenue       $ 11,000 14,900    
Deferred revenue, current         11,800    
Deferred revenue, noncurrent         $ 3,100    
Revenue, remaining performance obligation, amount             $ 15,700
Option to buy             $ 10,000
Contract with Customer, Liability, Revenue Recognized   $ 3,300